ArticleCancers2013
Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results.
Article in Cancers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice.Medical oncology (Northwood, London, England) · 2025Review
- Adjuvant Palbociclib May be Associated with Delayed Recurrence in Completely Resected Retroperitoneal Liposarcoma: Results of a Single-Institution Retrospective Cohort Study.Annals of surgical oncology · 2023Article
- Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time.Cancer research · 2023Article
- Pleomorphic Liposarcoma of Femur: A Rare Soft Tissue Sarcoma Metastasized to the Bone-Case Report and Review of Literature.Case reports in orthopedics · 2022Article
- Cross-flow microfiltration for isolation, selective capture and release of liposarcoma extracellular vesicles.Journal of extracellular vesicles · 2021Article
- Multi-Layer Micro-Nanofluidic Device for Isolation and Capture of Extracellular Vesicles Derived from Liposarcoma Cell Conditioned Media.Journal of microelectromechanical systems : a joint IEEE and ASME publication on microstructures, microactuators, microsensors, and microsystems · 2020Article
- Cracking the riddle of dedifferentiated liposarcoma: is EV-MDM2 a key?Oncoscience · 2020Article
- Complete regression of metastatic de-differentiated liposarcoma with engineered mesenchymal stromal cells with dTRAIL and HSV-TK.American journal of translational research · 2020Article
- A case report: a giant cardiac atypical lipoma associated with pericardium and right atrium.BMC cardiovascular disorders · 2019Article
- Editorial Comment to Laparoscopic-assisted surgery for liposarcoma of the spermatic cord extending to the retroperitoneal cavity through the internal inguinal ring.IJU case reports · 2019Article
- Adipogenesis and metabolic health.Nature reviews. Molecular cell biology · 2019Review
- Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model.BMC cancer · 2018Article
- Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma.Anticancer research · 2018Article
- Review
- miR-133a function in the pathogenesis of dedifferentiated liposarcoma.Cancer cell international · 2018Article
- Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.Oncotarget · 2017Article
- Innovative approaches to establish and characterize primary cultures: anBiology open · 2017Article
- Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma.Frontiers in oncology · 2017Review
- Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice.The Journal of experimental medicine · 2016Article
- Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.OncoTargets and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposarcoma is one of the most common adult soft tissue sarcomas and consists of three histologic subtypes (well and dedifferentiated, myxoid/round cell, and pleomorphic). Surgery is the mainstay of treatment for localized disease; however for unresectable or metastatic disease, effective treatment options are currently limited. In the past decade, a better understanding of the distinct genetic and molecular aberrations for each of the three histologic subtypes has led to the development of several novel systemic therapies. Data from phase I and early phase II clinical trials have been reported. Despite challenges with conducting clinical trials in liposarcoma, preliminary results for several of these novel, biology-driven therapies are encouraging.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.